Literature DB >> 17330175

Unified Wilson's Disease Rating Scale - a proposal for the neurological scoring of Wilson's disease patients.

Anna Członkowska1, Beata Tarnacka, Jens Carsten Möller, Barbara Leinweber, Oliver Bandmann, France Woimant, Wolfgang H Oertel.   

Abstract

BACKGROUND AND
PURPOSE: The clinical forms of Wilson's disease (WD) neurological manifestations can be divided into three movement disorder syndromes: a) dystonic, b) ataxic, c) parkinsonian syndrome. These syndromes in WD seldom occur in isolation. Clinical rating scales such as the Unified Parkinson;s Disease Rating Scale (UPDRS), the International Cooperative Ataxia Rating Scale (ICARS) and the Rating Scale for Dystonia (RSD), focusing on either parkinsonism or ataxia or dystonia alone, are not sufficient to reflect accurately the motor impairment of WD patients. The aim of the study was to develop a novel rating scale for WD, because as far as we know no scale for the clinical rating in WD has been designed before.
MATERIAL AND METHODS: In 2004 the EuroWilson consortium was founded, to create a European WD database. Members of the consortium from Poland, Germany, and France prepared a new scale using clinical rating scales as the UPDRS, ICARS, and RSD. Prepared drafts were discussed several times in detail at the first international neurological EuroWilson meeting in September 2004 in Paris and in November in Warsaw. RESULTS AND
CONCLUSIONS: The novel scale for WD consists of 3 parts, including: consciousness, a historical review based on the Barthel scale (2-11 items), and neurological examination (12-35, items). The maximum score for the first part is 3, for the second 39 points, and for the last 143 points. The initial reliability of the scale on the basis of 6 patients (on DVD) and 8 investigators was assessed. Inter-rater agreement was high. Now the scale is used by the EuroWilson and GeNeMove consortia.

Entities:  

Mesh:

Year:  2007        PMID: 17330175

Source DB:  PubMed          Journal:  Neurol Neurochir Pol        ISSN: 0028-3843            Impact factor:   1.621


  30 in total

1.  Measurement of urinary copper excretion after 48-h d-penicillamine cessation as a compliance assessment in Wilson's disease.

Authors:  Karolina Dzieżyc; Tomasz Litwin; Grzegorz Chabik; Anna Członkowska
Journal:  Funct Neurol       Date:  2015 Oct-Dec

Review 2.  Encephalopathy in Wilson disease: copper toxicity or liver failure?

Authors:  Peter Ferenci; Tomasz Litwin; Joanna Seniow; Anna Czlonkowska
Journal:  J Clin Exp Hepatol       Date:  2014-09-22

Review 3.  Neurologic impairment in Wilson disease.

Authors:  Petr Dusek; Tomasz Litwin; Anna Członkowska
Journal:  Ann Transl Med       Date:  2019-04

Review 4.  New tools for Wilson's disease diagnosis: exchangeable copper fraction.

Authors:  France Woimant; Nouzha Djebrani-Oussedik; Aurélia Poujois
Journal:  Ann Transl Med       Date:  2019-04

Review 5.  Wilson disease.

Authors:  Anna Członkowska; Tomasz Litwin; Petr Dusek; Peter Ferenci; Svetlana Lutsenko; Valentina Medici; Janusz K Rybakowski; Karl Heinz Weiss; Michael L Schilsky
Journal:  Nat Rev Dis Primers       Date:  2018-09-06       Impact factor: 52.329

6.  Movement Disorder in Wilson Disease: Correlation with MRI and Biomarkers of Cell Injury.

Authors:  Jayantee Kalita; Vijay Kumar; Usha K Misra; Sunil Kumar
Journal:  J Mol Neurosci       Date:  2020-07-13       Impact factor: 3.444

7.  Bone status and fractures in 85 adults with Wilson's disease.

Authors:  A-S Quemeneur; J-M Trocello; H-K Ea; A Ostertag; A Leyendecker; J-C Duclos-Vallée; M-C de Vernejoul; F Woimant; F Lioté
Journal:  Osteoporos Int       Date:  2014-07-16       Impact factor: 4.507

Review 8.  Evolving perspectives in Wilson disease: diagnosis, treatment and monitoring.

Authors:  Karl Heinz Weiss; Wolfgang Stremmel
Journal:  Curr Gastroenterol Rep       Date:  2012-02

9.  Structural and neurochemical evaluation of the brain and pons in patients with Wilson's disease.

Authors:  Oktay Algin; Ozlem Taskapilioglu; Bahattin Hakyemez; Gokhan Ocakoglu; Sukran Yurtogullari; Sevda Erer; Mufit Parlak
Journal:  Jpn J Radiol       Date:  2010-11-27       Impact factor: 2.374

10.  Inhibitory rTMS applied on somatosensory cortex in Wilson's disease patients with hand dystonia.

Authors:  Pierre Lozeron; Aurélia Poujois; Elodie Meppiel; Sana Masmoudi; Thierry Peron Magnan; Eric Vicaut; Emmanuel Houdart; Jean-Pierre Guichard; Jean-Marc Trocello; France Woimant; Nathalie Kubis
Journal:  J Neural Transm (Vienna)       Date:  2017-07-08       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.